


## Dolastatin 10

<b>Cat. No.:</b>	HY-15580
<b>CAS No.:</b>	110417-88-4
<b>Molecular Formula:</b>	C <sub>42</sub> H <sub>68</sub> N <sub>6</sub> O <sub>6</sub> S
<b>Molecular Weight:</b>	785.09
<b>Target:</b>	Microtubule/Tubulin; ADC Cytotoxin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	Powder    -80°C    2 years -20°C    1 year



\* The compound is unstable in solutions, freshly prepared is recommended.

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (127.37 mM)  
\* "≥" means soluble, but saturation unknown.

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.2737 mL	6.3687 mL	12.7374 mL
	5 mM	0.2547 mL	1.2737 mL	2.5475 mL
	10 mM	0.1274 mL	0.6369 mL	1.2737 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Dolastatin 10 (DLS 10) is a potent antimetabolic peptide that inhibits tubulin polymerization.
<b>IC<sub>50</sub> &amp; Target</b>	Auristatin
<b>In Vitro</b>	<p>Dolastatin 10 is a unique pentapeptide that isolated from the sea hare <i>Dolabella auricularia</i>. These in vitro data are quite comparable to those of Dolastatin 10 and Auristatin PE, each of which has GI<sub>50</sub> values of 10<sup>-5</sup>-10<sup>-6</sup> μg/mL (10<sup>-2</sup>-10<sup>-3</sup> nM) against a similar minipanel of human cell lines<sup>[2]</sup>. The antibody-drug conjugate (ADC) comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), a synthetic analog of the tubulin polymerization inhibitor Dolastatin 10<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### REFERENCES

[1]. Pitot HC, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999 Mar;5(3):525-31.

---

[2]. Pettit GR, et al. Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10. J Nat Prod. 2011 May 27;74(5):962-8.

[3]. Brentuximab vedotin. Drugs R D. 2011;11(1):85-95.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA